Our findings showed that both 5‐ASA and anti‐TNF agents are able to decrease the mucosal expression of LCN2, NOS2, and TFF1, the levels of which are overexpressed in untreated patients compared to non‐IBD controls. This evidence concerns the gene TFF1 and inflammatory bowel disease.